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Table 1. Functional groups of mutated proteins
Functional group of mutated proteins Mutated protein†
Desmin filament network
Calcium handling
Desmosomal
Nuclear envelope
Sarcomeric
2 desmin, 1 alpha-B-crystallin
8 phospholamban
2 plakophilin-2, 1 desmoplakin
4 lamin A/C
3 titin, 2 myosin binding protein C3,1 myosin heavy chain 7, 1 troponin T2, 1 Troponin I3
† The exact gene and protein mutations are shown in supplementary file 2.
Table 2. Patient characteristics per mutation group
Desminopathy
n=3
Phospholamban
n=8
Desmosomal
n=3
Lamin A/C
n=4
Sarcomeric
n=8
Total
n=26
Age at diagnosis
(yrs±SD)
40±2 36±13 34±7 48±8 27±16 36±14
Sex (m/f) 2/1 3/5 2/1 3/1 5/3 15/11
Initial clinical
diagnosis
2 DCM
1 ACM
6 DCM
2 ACM
3 ACM 4 DCM
5 DCM
3 HCM
17 DCM
6 ACM
3 HCM
LVAD 2/3 (67%) 5 /8(63%) 0/3 (0%) 3/4(75%) 3 (30%) 13 (50%)
ICD/PM/CRT-D 3 /3(100%) 7/8 (88%) 3/3 (100%) 3/4 (75%) 6 (75%) 22 (85%)
DCM = dilated cardiomyopathy, HCM = hypertrophic cardiomyopathy, ACM = arrhythmogenic cardiomyopathy, LVAD = left ventricular assist
device, ICD = Implantable Cardioverter Defibrillator, PM = pacemaker, CRT-D = Cardiac Resynchronization Therapy Device.
Table 3. Distribution pattern of fibrosis and adipose tissue in different mutation groups
MHC 7 = myosin heavy chain 7; MBPC3 = myosin binding protein C3. The schemes of the subgroups
in the sarcomeric group are shown in supplementary figure 5.
† LV fibrosis was more pronounced in the PLN group (27% [22-39]) than in the desmosomal group
(15% [14-17], p=0.024).
‡ A trend towards more adipose tissue in the RV in desmosomal group (46% [43-53]) compared to
PLN group (28% [26-39], p=0.07) was found.
§ No difference in fibrosis and fatty replacement between patients that initially presented with ACM
or DCM.
¶ In 1 patient also fibrosis in the outer part of the LV.
Mutation group Left ventricle Right ventricle
Desminopathies - Outer compact myocardium most
affected, location varying per patient
- Interstitial fibrosis, some fibrofatty
replacement in 2/3 patients
- Minor to moderate fibrosis
- Fibrofatty replacement in 1/3 patients
Desmosomal - Outer compact myocardium
posterolateral wall most affected
- Fibrofatty replacement and interstitial
fibrosis†
Fibrofatty replacement ‡
Phospholamban - Outer compact myocardium of
posterolateral wall most affected
- Interstitial fibrosis and fibrofatty
replacement †§
Fibrofatty replacement‡
Lamin A/C - Predominantly circumferential
trabecular and midmyocardial (inner
compact myocardium) ¶
- Interstitial fibrosis, no adipose tissue
Minor to moderate fibrosis without
increased fatty infiltration
Sarcomeric 1
Titin
Troponin T2
Troponin I3
MHC 7
- Predominantly circumferential
trabecular and midmyocardial (inner
compact myocardium)
- Interstitial fibrosis, no adipose tissue
Minor to moderate fibrosis without
increased fatty infiltration
Sarcomeric 2
MYBPC3
- Septum, anterior and posterior wall
most affected
- Replacement fibrosis and interstitial
fibrosis
Minor to moderate fibrosis anterior and
posterior wall
